Revealing the hidden impact of SGLT2 inhibitors on uric acid levels: a retrospective multicenter cohort study
These findings suggest that SGLT2i may serve as an adjunct therapy for hyperuricemia, especially in patients with DM & HF, highlighting the need for further research on long-term benefits.
Authors
- Abdullah A. Alahmed (ORCID: https://orcid.org/0000-0002-4739-5535)
- Abdulrahman Alqarafi (ORCID: https://orcid.org/0000-0002-3155-9216)
- Ehsan Habeeb (ORCID: https://orcid.org/0000-0002-0479-566X)
- Abdulmajeed M. Alshehri (ORCID: https://orcid.org/0000-0002-9104-5727)
- Ghalia Aquil
- Omar S. Alkhezi (ORCID: https://orcid.org/0000-0001-7714-2945)
- Ahmed Ghaith (ORCID: https://orcid.org/0000-0002-9102-1821)
- A. Afana
Institutions
- Qassim University (SA)
- King Saud bin Abdulaziz University for Health Sciences (SA)
- Taibah University (SA)
- King Faisal Specialist Hospital & Research Centre (SA)
- King Abdullah International Medical Research Center (SA)
- Prince Mohammed bin Abdulaziz Hospital (SA)
- National Guard Health Affairs (SA)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-10-20
- DOI
- https://doi.org/10.3389/fendo.2025.1667438
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 0.00